Recruiting

Testing a new cancer-fighting antibody medication for advanced tumors

Plain-English translation of NCT07127874 on ClinicalTrials.gov ↗ · Source last updated August 2026 · Translation generated August 2026 · How we translate trials

Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.

This is one of the first times this treatment has been tested in people.

What is this trial?

This is the first study of , a new type of cancer medication called an antibody-drug conjugate, being tested in people with advanced solid tumors that have stopped responding to standard treatments. Researchers want to find out if this medication is safe to use, how the body processes it, and whether it can help slow or shrink tumors. The medication works by targeting cancer cells and delivering treatment directly to them.

Many patients with advanced colon, lung, and pancreatic cancer run out of standard treatment options or cannot tolerate them. This trial exists to find out if this new medication could offer hope to people in this situation by testing whether it's safe and whether it works.

Do you qualify?

You likely qualify if…

you have been diagnosed with advanced colon cancer, lung cancer (non-small cell), or pancreatic cancer that has been confirmed by a biopsy
you have already received at least one prior cancer treatment and your cancer is growing or spreading despite treatment
you have measurable disease that can be seen on imaging scans
you are in good enough overall health to tolerate the study medication, with an ECOG performance status of 0 or 1
you have adequate organ function (healthy kidneys, liver, and heart function)
you have a tumor tissue sample available from a previous biopsy or surgery

You likely don't qualify if…

you have previously received treatment with another antibody-drug conjugate containing topoisomerase-1 inhibitors
you have brain metastases (cancer spread to the brain) that are not stable or controlled
you have ongoing side effects from previous cancer treatments that are moderate to severe
you have had lung inflammation or scarring (pneumonitis or interstitial lung disease) within the past 6 months
you have had major surgery within the past 28 days or have not recovered from a recent surgical procedure

What participation looks like

If you join this trial, you will receive intravenous infusions (through a vein) of the study medication. The trial is divided into two phases that gradually increase the dose to find the safest and most effective amount. You will need to visit the research center for infusions and to have blood tests, imaging scans, and other monitoring to check how your body is responding and to watch for any side effects. The trial will track your health over time to see how the medication affects your cancer.

AI-generated summary from trial data · Aug 11, 2026 · Not medical advice

Trial locations(26 sites)

United States

PHN-012-001 Site, Los Angeles, California

PHN-012-001 Site, San Diego, California

PHN-012-001 Site, Washington D.C., District of Columbia

PHN-012-001 Site, Boston, Massachusetts

PHN-012-001 Site, St Louis, Missouri